Dividend Distribution - The company plans to distribute a cash dividend of 1.5 RMB per 10 shares and issue 2 bonus shares for every 10 shares held, along with a capital reserve conversion of 1 share for every 10 shares[11]. - The company has maintained a clear and transparent cash dividend policy, ensuring the protection of minority shareholders' rights[174]. - The cash dividend represents 42.86% of the total distributable profit of 524,429,825.50 yuan[175]. - The total cash dividend amount for the 2021 fiscal year was 59,104,125 yuan (including tax), with no stock dividends issued[173]. - The company will also issue 2 bonus shares for every 10 shares held and increase the share capital by 1 share for every 10 shares held, resulting in a total increase of 119,212,410 shares[175]. Financial Performance - The company's operating revenue for 2022 was ¥1,336,002,647.93, representing a 14.75% increase compared to ¥1,164,288,763.57 in 2021[28]. - The net profit attributable to shareholders for 2022 was ¥184,634,263.09, an increase of 18.42% from ¥155,910,663.53 in 2021[28]. - The net cash flow from operating activities increased by 21.98% to ¥402,176,397.74 in 2022, up from ¥329,716,957.18 in 2021[28]. - The total assets at the end of 2022 reached ¥1,786,535,673.29, a 27.06% increase from ¥1,406,039,522.12 at the end of 2021[28]. - The basic earnings per share for 2022 was ¥0.4660, reflecting a 16.56% increase from ¥0.3998 in 2021[28]. Market Overview - The blood purification market is highly competitive, with significant price reductions due to centralized procurement policies, potentially impacting future profitability[10]. - The company is exploring opportunities for market expansion through centralized procurement, which could accelerate the domestic replacement process[10]. - The blood purification market in China increased from ¥9.9 billion in 2017 to ¥13.3 billion in 2021, with an average annual growth rate of 7.66%[54]. - By 2026, the blood purification medical device market in China is expected to reach ¥28 billion, with a CAGR of 16.3%[54]. - The number of end-stage renal disease patients in China rose from 2.5 million in 2017 to 3.6 million in 2021, accounting for over one-third of the global total[51]. Product Development and Innovation - The company is focused on the rapid innovation and iteration of its medical devices, including blood purification and infusion products, to maintain its market leadership[11]. - The company has developed a complete product chain for blood dialysis, including key technologies that are at an internationally advanced level[48]. - The company aims to enhance its market share through innovative products and services, leveraging the ongoing medical infrastructure development in China[44]. - The company has developed China's first three-level reverse osmosis blood dialysis water treatment system, which has been recognized as a major technological equipment[59]. - The company has introduced new products, including a disposable blood dialysis device and a PTA high-pressure balloon dilation catheter, which are expected to enhance its market position[113]. Regulatory and Compliance - The company operates in a heavily regulated industry, with strict requirements for product safety and efficacy[8]. - The company has received multiple certifications for its products, including CE certification for the EU and FDA certification for some products in the US[57]. - The company has participated in the formulation and revision of 2 national standards and 3 industry standards for infusion products, enhancing its competitive position in the market[68]. - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[136]. - The company has enhanced its internal control system in compliance with the latest regulations, ensuring effective governance and decision-making processes[181]. Research and Development - The company’s R&D investment reached ¥66,113,679.40 in 2022, accounting for 4.95% of its operating revenue[111]. - The company holds a total of 111 authorized patents and has 67 patent applications under review as of the end of the reporting period[111]. - The company has been recognized as a "National Intellectual Property Advantage Enterprise" for 2022 by the National Intellectual Property Administration[111]. - The company is currently applying for five medical device registration certificates, with three from the parent company and two from subsidiaries[112]. - The company has developed new infusion devices such as non-DEHP infusion sets and precision filter infusion sets, which have received positive feedback from clinical staff and patients[67]. Corporate Governance - The company has established effective communication channels with shareholders, ensuring their rights to information and decision-making are protected[137]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management, aligning with legal standards[142]. - The company has maintained independence from its controlling shareholders in terms of business, personnel, assets, and finance, ensuring autonomous operations[144]. - The company has a board of directors consisting of 7 members, including 3 independent directors, all of whom are of Chinese nationality[149]. - The company has a structured salary system based on job evaluation points, education, skills, experience, and company tenure[157]. Social Responsibility and Community Engagement - The company has actively participated in social welfare initiatives, including donations and support for local communities[195]. - The company organized over 300 volunteer service activities during the reporting period to support public health efforts amid ongoing challenges[195]. - The company has been recognized as a "Leading Enterprise in Social Responsibility" by the Jiangxi Provincial Federation of Industry and Commerce in 2022[195]. - The company has committed to fulfilling its tax obligations and maintaining transparency in its operations[194]. - The company has engaged in various community-building activities, fostering a positive work environment and employee morale[194].

Financial Performance - The company's operating revenue for 2022 was ¥1,336,002,647.93, representing a 14.75% increase from ¥1,164,288,763.57 in 2021[28]. - The net profit attributable to shareholders for 2022 was ¥184,634,263.09, an increase of 18.42% compared to ¥155,910,663.53 in 2021[28]. - The net cash flow from operating activities reached ¥402,176,397.74, up 21.98% from ¥329,716,957.18 in the previous year[28]. - The total assets at the end of 2022 amounted to ¥1,786,535,673.29, a 27.06% increase from ¥1,406,039,522.12 at the end of 2021[28]. - The basic earnings per share for 2022 was ¥0.4660, reflecting a 16.56% increase from ¥0.3998 in 2021[28]. - The weighted average return on equity for 2022 was 18.96%, slightly up from 18.64% in 2021[28]. - The company reported a net profit of ¥166,627,610.36 after deducting non-recurring gains and losses, which is a 14.77% increase from ¥145,190,265.25 in 2021[28]. - The company received government subsidies amounting to ¥23,744,029.94 in 2022, compared to ¥17,898,922.83 in 2021[33]. - The company achieved operating revenue of 1,336.00 million yuan, a year-on-year increase of 14.75%[94]. - Net profit attributable to shareholders reached 184.63 million yuan, up 18.42% compared to the previous year[94]. - Blood purification products generated revenue of 882.12 million yuan, representing a growth of 19.91% and accounting for 66.03% of total revenue[94]. Market Position and Competition - The company operates in a highly competitive blood purification market, with significant price reductions due to centralized procurement policies, potentially impacting future profitability[10]. - The company is focused on the rapid innovation and iteration of its medical devices, including blood purification and infusion products, to maintain its market leadership[11]. - The company is committed to expanding its market share through successful bids in centralized procurement processes, which can lead to significant market share gains[10]. - The company has achieved a market share of approximately 10%-20% for domestic blood dialysis machines, while imported machines dominate the market with an 80%-90% share[56]. - The company is a leading player in the blood purification industry, having established a complete product chain for blood dialysis equipment and consumables, with a strong brand influence in the market[57]. - The company has established a global marketing system, with products and services sold in over 60 countries and regions[91]. Product Development and Innovation - The company emphasizes the importance of maintaining strict quality control measures, as its main products are classified as Class III medical devices, which are subject to rigorous regulatory scrutiny[9]. - The company has developed a complete product chain for blood dialysis, including key technologies that are at an internationally advanced level[48]. - The company has completed the full industrial chain layout for blood dialysis consumables, ensuring a solid foundation for rapid revenue growth over the past decade[60]. - The company has added new medical devices, including a disposable blood dialysis device and a PTA high-pressure balloon dilation catheter, enhancing its product portfolio[113]. - The company has developed a range of infusion products, including safety injection devices and precision filtration infusion systems, to meet diverse patient needs[67]. - The company’s PTA high-pressure balloon catheter has achieved industry-leading performance indicators, enhancing its competitive edge in the market[64]. - The company has participated in the formulation and revision of 2 national standards and 3 industry standards for infusion products, enhancing its competitive position in the market[68]. Regulatory and Compliance - The company faces risks related to national policy changes that could alter the competitive landscape of the medical device industry[7]. - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[136]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management, aligning with legal standards[142]. - The company has enhanced its internal control system in compliance with the latest regulations, ensuring effective governance and decision-making processes[181]. - The company has established internal and external supervision systems to protect shareholder rights and ensure transparency in decision-making processes[193]. Corporate Social Responsibility - The company has focused on enhancing employee welfare while contributing to the advancement of health initiatives, reflecting its commitment to social responsibility[193]. - The company actively created employment opportunities, absorbing over 1,000 urban and rural residents for job creation, contributing to rural revitalization efforts[196]. - The company organized over 300 volunteer service activities during the reporting period to support public health efforts amid ongoing challenges[195]. - The company has been awarded the title of "Major Taxpayer Enterprise" multiple times, reflecting its commitment to integrity in business operations[198]. - The company was recognized as a "Leading Enterprise in Social Responsibility" by the Jiangxi Provincial Federation of Industry and Commerce in 2022[195]. Research and Development - The company has built a strong R&D foundation, participating in the formulation of 2 national standards and 9 industry standards[94]. - The company’s R&D investment reached ¥66,113,679.40 in 2022, accounting for 4.95% of its operating revenue[111]. - The number of R&D personnel increased to 249 in 2022, representing a growth of 0.81% compared to 2021[111]. - The company holds a total of 111 authorized patents and has 67 patent applications under review as of the end of the reporting period[111]. - The company aims to enhance its core competitiveness through the implementation of new product projects, including needle-free injection systems and CRRT tubing[110]. Shareholder Engagement and Governance - The annual shareholders' meeting had a participation rate of 30.58% in April 2022, reflecting shareholder engagement[145]. - The first extraordinary shareholders' meeting in June 2022 had a participation rate of 30.57%, indicating continued shareholder involvement[145]. - The company has established effective communication channels with shareholders, ensuring their rights to information and decision-making are protected[137]. - The company has not experienced any violations by controlling shareholders regarding the appropriation of company funds or assets during the reporting period[140]. - The company has a structured salary system based on job evaluation points, education, skills, experience, and tenure[157]. Environmental Responsibility - The company has implemented measures to reduce carbon emissions, including the use of advanced production processes and lightweight materials, contributing to energy savings[190]. - The company has a comprehensive environmental management system in place to ensure compliance with pollution discharge standards and promote clean production practices[190]. - The company has not reported any significant environmental penalties during the reporting period, indicating compliance with environmental regulations[188].

证券代码：300453 证券简称：三鑫医疗 公告编号：2023-021 江西三鑫医疗科技股份有限公司 关于举行2022年度业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）已于2023年3月23日在巨 潮资讯网（http://www.cninfo.com.cn/）上披露了《<2022年年度报告全文>及其摘 要》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年3月31 日（星期五）下午15：00至17：00举行2022年度网上业绩说明会。本次年度业绩说 明会将通过深圳证券交易所提供的"互动易"平台和深圳价值在线信息科技股份有 限公司提供的"价值在线"平台采用网络远程的方式同步举行。 参与方式一：通过深圳证券交易所提供的"互动易"平台举行，投资者可登陆 "互动易"网站（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次业 绩说明会。 参与方式二：投资者可于2023年3月31日（星期五）下午15:00-17:00通过网址 https://eseb.cn/ ...

Group 1: Impact of COVID-19 and Business Performance - The pandemic has had a certain impact on the company's operations, but the first quarter report shows stable growth, indicating that annual growth remains promising [2][3]. - The company expects a net profit growth of over 100% for Q1 2020 compared to the same period last year [5]. Group 2: Market and Product Development - The company has received over 10 million orders for masks, primarily exporting to Europe [3]. - The company is focusing on expanding its market share in blood purification products, which have shown continuous revenue growth [3][4]. - The company has developed a dialysis tube with an annual production capacity of nearly 20 million sets, significantly exceeding the import ratio [5]. Group 3: Strategic Initiatives and Future Plans - The company actively participates in volume-based procurement, which has increased product sales and market share without significantly affecting factory prices [4]. - The company plans to continue expanding production capacity for blood purification products as the market grows [3][4]. - The company is open to refinancing based on operational needs and is committed to mergers and acquisitions to strengthen its position in the blood purification industry [4][8]. Group 4: Research and Development - The company has made significant breakthroughs in the research of hollow fiber dialysis membrane materials, reducing reliance on foreign technology [6]. - The company invests heavily in R&D to support sustainable growth in the medical device sector, despite the long development cycles [7]. Group 5: Market Position and Competition - The company’s products have received CE certification for entry into the EU market, and it has established a mature overseas sales network, exporting to Europe, Southeast Asia, Africa, and South America [7]. - The company does not see direct competition with certain other brands in the dialysis field, as their products serve different medical needs [5][7].

江西三鑫医疗科技股份有限公司 2022 年第三季度报告 证券代码：300453 证券简称：三鑫医疗 公告编号：2022-052 江西三鑫医疗科技股份有限公司 2022年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 324,351,752.18 | 2.17% | 984,555,678.59 | 19.13% | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥660,203,926.41, representing a 29.71% increase compared to ¥508,993,232.09 in the same period last year[24]. - The net profit attributable to shareholders for the first half of 2022 was ¥104,736,931.56, a 47.17% increase from ¥71,169,206.67 in the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,496,899.72, up 48.15% from ¥66,485,208.09 in the same period last year[24]. - The net cash flow from operating activities was ¥87,312,813.69, an increase of 8.16% compared to ¥80,722,586.52 in the previous year[24]. - The total assets at the end of the reporting period were ¥1,587,298,006.53, reflecting a 12.89% increase from ¥1,406,039,522.12 at the end of the previous year[24]. - The net assets attributable to shareholders at the end of the reporting period were ¥965,556,400.66, a 6.63% increase from ¥905,506,389.18 at the end of the previous year[24]. - The basic earnings per share for the first half of 2022 were ¥0.2658, up 47.18% from ¥0.1806 in the same period last year[24]. - The diluted earnings per share for the first half of 2022 were also ¥0.2658, reflecting a 47.18% increase compared to ¥0.1806 in the previous year[24]. - The weighted average return on equity was 12.77%, an increase of 3.91% from 8.86% in the previous year[24]. Product Development and Market Position - The company has transformed from traditional infusion products to a leading provider of comprehensive blood purification solutions, covering five major product series: blood purification, injection, indwelling catheter, infusion and blood transfusion, and thoracic surgery[32]. - The company has established a nationwide production layout for blood purification, with its subsidiary Chengdu Weili Sheng recognized as a leading provider of blood dialysis equipment in China[35]. - The company has developed a second production line for hollow fiber blood dialysis membranes, which is expected to enhance production capacity and improve product efficiency[36]. - The company holds a high market share in blood dialysis concentrates and has automated its production line from input to packaging[36]. - The company actively participates in the formulation and revision of national and industry standards, having completed 2 national standards and 3 industry standards[37]. - The company aims to be a top manufacturer in the medical consumables sector and is focused on developing new products to enhance its market position[38]. - The company has established itself as an operator in the blood purification industry, focusing on products for end-stage renal disease (ESRD) patients[40]. - The core product of the blood purification segment is the hemodialyzer, which utilizes hollow fiber membrane technology for effective blood treatment[43]. - The company’s hemodialysis machine (model W-T2008-B) and hemodialysis filter machine (model W-T6008S) are designed for adult chronic kidney failure patients, ensuring precise control of treatment parameters[43]. - The market share of the company's dialysis solution products ranks among the top in the domestic market[43]. - The company has an annual production capacity of over 2,000 sets for dialysis tubing[43]. - The hemodialysis products are essential for both acute and chronic kidney failure patients, providing necessary electrolytes and correcting acid-base imbalances during treatment[43]. - The company is committed to continuous innovation and development in the blood purification product line to meet diverse patient needs[40]. - The company’s products are designed to ensure safety and efficiency in clinical settings, with a focus on enhancing patient care[45]. Revenue Breakdown - Blood purification products generated revenue of 404.49 million yuan, accounting for 61.27% of total revenue, with a growth of 20.71% compared to the previous year[56]. - Injection products saw revenue of 134.09 million yuan, representing a significant increase of 94.67%, with vaccine syringe sales reaching 359 million units, up 240% year-on-year[56]. - The company reported a 31.02% increase in revenue from infusion and blood transfusion products, totaling 39.21 million yuan, which accounted for 5.94% of total revenue[57]. Research and Development - The company invested CNY 29.54 million in R&D during the reporting period, accounting for 4.47% of its revenue, with a year-on-year increase of 27.87%[73]. - The company holds 111 authorized patents and has 62 patents under application, along with 86 registered medical device certificates[73]. - The company has a strong R&D team and capabilities, having established several research centers and participated in the formulation of 2 national standards and 8 industry standards[78]. Strategic Initiatives - The company is actively exploring market expansion opportunities to strengthen its position in the healthcare sector[40]. - The company aims to enhance operational efficiency through strategic partnerships and technological advancements in its product offerings[40]. - The company formed a high-performance medical device industry innovation consortium in Jiangxi Province, collaborating with 13 research institutions and 23 industry representatives to drive technological advancements[59]. Environmental and Social Responsibility - The company has established a wastewater management system based on the principle of "rainwater and sewage diversion," ensuring that domestic wastewater is pre-treated before being sent to the park's sewage treatment plant for further processing[113]. - The company has implemented measures to reduce carbon emissions, including the use of advanced production processes and energy-saving equipment, which have led to a decrease in energy consumption and carbon emissions[113]. - The company actively engages in social responsibility initiatives, including donations of medical supplies during the COVID-19 pandemic and support for local employment and rural revitalization[117]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[8]. - The company appointed a new deputy general manager, Leng Lingli, on March 15, 2022[107]. - The company has implemented a restricted stock incentive plan, granting 8.5 million shares at a price of 6.43 CNY per share to 93 eligible participants[109]. - The company’s major shareholders, including Peng Yixing and Lei Fenglian, committed to not reducing their shareholdings within three years post-IPO[120]. - The company reported that there were no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[123]. - There were no violations of external guarantees during the reporting period[124]. - The company has not experienced any bankruptcy reorganization matters during the reporting period[126]. Risks and Challenges - The company faces risks related to national policy changes that could impact the competitive landscape of the medical device industry[102]. - Quality control risks are significant due to the nature of the company's products being classified as Class III medical devices, which are subject to strict regulatory scrutiny[102]. - Rising raw material prices pose a risk to profit margins, influenced by the complex international political and economic environment[102].

Financial Performance - The company's revenue for Q1 2022 was CNY 321,497,637.25, representing a 30.61% increase compared to CNY 246,148,032.60 in the same period last year[4] - Net profit attributable to shareholders was CNY 47,447,455.87, up 39.37% from CNY 34,044,129.84 year-on-year[4] - Basic earnings per share rose to CNY 0.1204, a 39.35% increase from CNY 0.0864 in the same period last year[4] - Total operating revenue for Q1 2022 reached ¥321,497,637.25, an increase of 30.6% compared to ¥246,148,032.60 in Q1 2021[20] - Net profit for Q1 2022 was ¥50,359,581.15, representing a 34.5% increase from ¥37,411,131.05 in Q1 2021[21] - Earnings per share for Q1 2022 were ¥0.1204, compared to ¥0.0864 in Q1 2021, reflecting a growth of 39.3%[22] Cash Flow - The net cash flow from operating activities increased by 127.00%, reaching CNY 14,868,783.06 compared to CNY 6,550,259.90 in the previous year[4] - Cash flow from operating activities in Q1 2022 was ¥350,610,682.58, an increase of 32.6% from ¥264,314,438.96 in Q1 2021[23] - The net cash flow from operating activities for Q1 2022 was ¥14,868,783.06, an increase from ¥6,550,259.90 in Q1 2021, representing a growth of approximately 127%[24] - The total cash outflow from operating activities was ¥335,741,899.52, compared to ¥257,764,179.06 in the previous year, reflecting an increase of approximately 30%[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,442,878,734.42, reflecting a 2.62% increase from CNY 1,406,039,522.12 at the end of the previous year[4] - The total liabilities decreased from CNY 379,357,648.27 to CNY 353,107,022.77, a reduction of approximately 6.9%[17] - Current assets amounted to CNY 588,432,679.18, up from CNY 548,228,432.28 at the start of the year, indicating an increase of about 7.3%[16] - The company’s long-term assets totaled CNY 854,446,055.24, slightly down from CNY 857,811,089.84 at the beginning of the year[17] - Total liabilities as of Q1 2022 were ¥406,477,102.44, a decrease from ¥427,244,790.66 in the previous year[21] Equity - The company's equity attributable to shareholders increased by 6.01%, amounting to CNY 959,968,858.03 compared to CNY 905,506,389.18 at the end of the last year[4] - Total equity attributable to shareholders of the parent company was ¥959,968,858.03, an increase of 6.0% from ¥905,506,389.18 in Q1 2021[21] Expenses - Research and development expenses increased by 72.34% to CNY 9,481,656.95, driven by increased investment in R&D projects[8] - Management expenses rose significantly by 98.56% to CNY 25,646,319.89, primarily due to increased stock incentive expenses[8] - Research and development expenses for Q1 2022 amounted to ¥9,481,656.95, up 72.5% from ¥5,501,825.94 in Q1 2021, indicating a strong focus on innovation[21] Market Strategy - The company plans to continue expanding its market presence in blood purification products, which have shown sustained revenue growth[8] - The company plans to invest CNY 568 million in a new research and production base for blood dialysis products, which is expected to enhance production capacity and support future business expansion[14] Sales Performance - The company reported a significant increase in sales collection, contributing to the rise in operating cash flow[8] - The company reported cash received from sales, totaling ¥332,918,108.44 in Q1 2022, compared to ¥250,206,117.69 in Q1 2021, reflecting strong sales performance[23]

Financial Performance - The company's operating revenue for 2021 was ¥1,164,288,763.57, representing a 23.81% increase compared to ¥940,385,589.06 in 2020[24]. - The net profit attributable to shareholders for 2021 was ¥155,910,663.53, a 34.84% increase from ¥115,624,846.75 in 2020[24]. - The net profit after deducting non-recurring gains and losses was ¥145,190,265.25, up 43.68% from ¥101,050,763.98 in 2020[24]. - The company's cash flow from operating activities for 2021 was ¥329,716,957.18, a 20.82% increase from ¥272,895,487.24 in 2020[24]. - The total assets at the end of 2021 were ¥1,406,039,522.12, reflecting a 12.96% increase from ¥1,244,754,307.25 at the end of 2020[24]. - The net assets attributable to shareholders at the end of 2021 were ¥905,506,389.18, a 15.32% increase from ¥785,198,391.69 at the end of 2020[24]. - The company achieved operating revenue of CNY 1,164.29 million, a year-on-year increase of 23.81%[90]. - Net profit attributable to shareholders reached CNY 155.91 million, up 34.84% compared to the previous year[82]. - The total revenue for 2021 was approximately CNY 1.28 billion, representing an increase of 18.22% compared to CNY 1.08 billion in 2020[105]. Dividend Distribution - The company plans to distribute a cash dividend of 1.50 RMB per 10 shares to all shareholders, based on a total of 394,027,500 shares[9]. - The company distributed a cash dividend of RMB 2.00 per 10 shares, totaling RMB 52,537,000, and issued 1.5 bonus shares per 10 shares, along with a capital increase of 3.5 shares per 10 shares, increasing the total share capital to 394,027,500 shares[161]. - The total distributable profit for the year was RMB 416,784,890.37, with the cash dividend accounting for 100% of the profit distribution[163]. - The company's cash dividend policy complies with the company's articles of association and provides clear standards and procedures for distribution[162]. Market Position and Strategy - The company is focused on expanding its market presence and developing new products and technologies to enhance competitiveness[6]. - The company has established several wholly-owned and controlling subsidiaries to enhance its operational capabilities and market reach[17]. - The company has been recognized as a leading enterprise in the blood purification industry, providing a full range of products including dialysis machines and related consumables[40]. - The company aims to expand its market presence through strategic initiatives and product innovation in the medical device sector[47]. - The company has a strong brand presence in the blood purification market, with its products gaining recognition and trust among customers[81]. - The company plans to continue expanding its market share in blood purification products and enhance its product structure through new developments[85]. Research and Development - The company has a strong R&D team and capabilities, having established multiple research centers and contributed to the formulation of 2 national standards and 8 industry standards[78]. - The company’s R&D investment for 2021 was CNY 61.19 million, accounting for 5.26% of total revenue, representing a year-on-year increase of 30.29%[102]. - The number of R&D personnel increased to 247 in 2021, up 9.78% from 225 in 2020, with R&D personnel now making up 13.15% of the total workforce[102]. - The company is focused on reducing the economic burden on patients by promoting domestic alternatives to imported products[102]. - The company aims to enhance its core competitiveness and market expansion capabilities through the development of new products[102]. Regulatory and Compliance - The company operates in a highly regulated medical device industry, which is subject to strict national policies and quality control standards[6][7]. - The company has received various certifications, including CE and FDA510(k), ensuring compliance with international quality standards[79]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management[130]. - The company has established and optimized internal control systems in accordance with the latest regulations, ensuring effective governance and decision-making processes[171]. - There were no significant internal control deficiencies identified during the reporting period, with all financial and non-financial reporting controls deemed effective[172]. Corporate Governance - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team[124]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[126]. - The company maintains independence from its controlling shareholders in terms of business, personnel, assets, and finance[132]. - The company actively engages with shareholders through various communication channels to ensure their rights are protected[125]. - The company’s board has been proactive in enhancing the operational standards and protecting the rights of minority shareholders[152]. Social Responsibility and Sustainability - The company has actively engaged in social responsibility initiatives, emphasizing employee welfare and contributions to health advancements[181]. - The company has implemented measures to reduce carbon emissions, including the use of clean energy sources and optimizing production locations to minimize transportation emissions[180]. - The company was recognized as a "2021 Occupational Health Demonstration Enterprise" in Nanchang, reflecting its commitment to workplace safety and health[179]. - The company actively creates job opportunities to support rural employment and talent development[184]. - The company has implemented a procurement management system to maintain a win-win situation with suppliers[183]. Product Development and Innovation - The company has continuously optimized its product structure, transitioning from traditional infusion to a comprehensive range of medical devices across six major segments[33]. - The company has established a complete industrial chain from blood purification consumables to equipment, positioning itself as a leader in the industry[35]. - The company reported a significant focus on the development of single-use sterile injection devices, which are designed to minimize injection pain for insulin administration[57]. - The introduction of a closed intravenous catheter system allows for a needle-free connection, reducing the workload for healthcare professionals[59]. - The company is expanding its product line to include light-protective infusion devices, which are essential for administering light-sensitive medications[63].

Financial Performance - The company's revenue for Q3 2021 reached ¥317,476,887.58, representing a 29.40% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥43,331,185.29, up 15.33% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥38,926,344.26, reflecting a 29.19% increase compared to the previous year[4] - Total operating revenue for Q3 2021 reached ¥826,470,119.67, an increase of 20.5% compared to ¥681,997,820.49 in the same period last year[25] - Operating profit for Q3 2021 was ¥149,963,191.98, up 34.7% from ¥111,249,387.48 in Q3 2020[26] - Net profit for Q3 2021 was ¥126,824,272.64, representing a 40.9% increase from ¥89,990,501.62 in Q3 2020[26] - Basic and diluted earnings per share for Q3 2021 were both ¥0.2906, compared to ¥0.2083 in the same quarter last year, reflecting a 39.4% increase[27] - The company reported a total comprehensive income of ¥126,824,272.64 for Q3 2021, compared to ¥89,990,501.62 in Q3 2020, an increase of 40.9%[27] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥1,311,151,511.94, a 5.33% increase from the end of the previous year[4] - Total assets as of Q3 2021 amounted to ¥1,311,151,511.94, up from ¥1,244,754,307.25 at the end of Q3 2020, marking a growth of 5.3%[23] - Total liabilities decreased to ¥392,213,208.85 in Q3 2021 from ¥399,519,382.95 in Q3 2020, a reduction of 1.8%[23] - The company's non-current assets totaled ¥813,294,159.05, an increase of 5.8% from ¥768,903,358.53 in the previous year[23] Cash Flow - Cash flow from operating activities for the year-to-date was ¥202,443,690.56, showing an 18.88% increase[4] - Operating cash inflow for the current period reached ¥890,964,419.65, an increase of 5.4% compared to ¥845,491,338.30 in the previous period[28] - Net cash flow from operating activities was ¥202,443,690.56, up 18.9% from ¥170,292,205.53 in the prior year[30] - Total cash outflow from operating activities was ¥688,520,729.09, compared to ¥675,199,132.77 in the previous period[30] - Cash inflow from investment activities totaled ¥466,712,451.95, down 13.5% from ¥539,457,765.52 in the previous period[30] - Net cash flow from investment activities was -¥27,901,018.83, an improvement from -¥174,006,239.84 in the prior year[30] - Cash inflow from financing activities was ¥101,600,002.00, down 32% from ¥149,358,730.95 in the previous period[30] - Net cash flow from financing activities was -¥115,070,420.90, worsening from -¥50,694,224.38 in the previous year[30] - The ending balance of cash and cash equivalents was ¥150,857,709.39, significantly up from ¥49,812,723.41 in the previous period[30] Equity and Shareholder Information - The weighted average return on equity for the year-to-date was 14.08%, an increase of 1.02% compared to the previous year[4] - The company’s basic earnings per share for Q3 2021 was ¥0.1100, a 15.30% increase year-on-year[4] - The total equity attributable to shareholders increased to ¥849,379,974.98, an 8.17% rise from the previous year-end[4] - The company approved a restricted stock incentive plan to issue up to 8.5 million shares at a price of CNY 6.43 per share, representing 2.16% of the total share capital[18] - The total estimated expense for the restricted stock incentive plan from 2021 to 2024 is projected to be CNY 56.62 million[19] Current Assets and Inventory - As of September 30, 2021, the company's total current assets amounted to CNY 497,857,352.89, an increase from CNY 475,850,948.72 at the end of 2020, representing a growth of approximately 4.2%[21] - Cash and cash equivalents increased to CNY 175,539,659.39 from CNY 98,264,811.59, showing a significant rise of approximately 78.5%[21] - Accounts receivable rose to CNY 105,423,215.44 from CNY 93,967,507.50, reflecting an increase of about 12.2%[21] - Inventory levels were reported at CNY 148,509,654.86, slightly up from CNY 143,316,557.53, indicating a growth of approximately 3.0%[21] - The company’s fixed assets increased to CNY 483,449,080.05 from CNY 467,012,829.99, marking a growth of approximately 3.5%[21] - Long-term receivables decreased slightly to CNY 5,477,431.62 from CNY 5,768,103.91, a decline of about 5.0%[21] - The company’s total non-current assets include CNY 10,000,000.00 in debt investments, unchanged from the previous period[21] Research and Development - Research and development expenses for Q3 2021 were ¥23,334,153.88, up 28.0% from ¥18,267,008.25 in Q3 2020, indicating a focus on innovation[26] Government Subsidies - The company received government subsidies amounting to ¥7,451,194.42 during the reporting period[5] Employee Compensation - Employee compensation payments increased to ¥139,007,908.95, up 27.5% from ¥109,051,774.28 in the previous period[28] Deferred Income - Deferred income increased to ¥35,813,500.20 from ¥23,742,502.81, reflecting a growth of 50.8% year-over-year[23]

Financial Performance - The company achieved operating revenue of ¥508,993,232.09, representing a year-on-year increase of 16.57%[24]. - Net profit attributable to shareholders reached ¥71,169,206.67, marking a significant growth of 59.98% compared to the same period last year[24]. - The net profit after deducting non-recurring gains and losses was ¥66,485,208.08, an increase of 51.47% year-on-year[24]. - The company reported a basic earnings per share of ¥0.1806, up 59.96% from the previous year[24]. - The company's operating income for the first half of 2021 was CNY 424,762,830.43, an increase of 13.09% compared to CNY 375,625,539.02 in the same period of 2020[178]. - Net profit for the first half of 2021 reached CNY 79,169,132.27, representing a 61.41% increase from CNY 49,074,222.19 in the first half of 2020[175]. - The total profit for the first half of 2021 was CNY 90,851,165.40, an increase of 54.67% compared to CNY 58,739,988.92 in the first half of 2020[175]. Share Capital and Dividends - The company reported a total increase in share capital of 131,342,500 shares due to a rights distribution, resulting in a change in basic and diluted earnings per share from RMB 0.1693 to RMB 0.1129[23]. - The company does not plan to distribute cash dividends or issue bonus shares[9]. - The company completed a rights distribution on April 29, 2021, distributing 1.5 shares for every 10 shares held and increasing the total share capital by 131,342,500 shares, resulting in a new total of 394,027,500 shares[143]. - The cash dividend distributed was RMB 2.00 per share, totaling RMB 52,537,000 (including tax) based on the total share capital of 262,685,000 shares as of December 31, 2020[143]. Market and Industry Context - The company operates in a highly regulated medical device industry, which is subject to significant national policy risks that could impact its operations[5]. - The ongoing reform of the medical insurance system aims to optimize the medical insurance catalog, which will include high-value clinical products, enhancing market access for the company's offerings[58]. - The domestic substitution of high-end medical devices is accelerating, with increased reimbursement rates for domestic products, enhancing their competitiveness in the market[60]. - The demand for medical devices in county-level hospitals is expected to rise significantly due to government initiatives to improve healthcare capabilities[61]. - The aging population and rising chronic diseases are projected to increase the number of end-stage renal disease patients in China to over 4 million by 2030[63]. - The Chinese medical device market has grown by nearly 400 billion RMB from 2014 to 2019, with an average annual growth rate of around 20%, significantly outpacing the global market[65]. Product Development and Innovation - The company focuses on continuous product development and has transitioned to providing comprehensive blood purification solutions[31]. - The company is expanding its market presence by enhancing product offerings in the injection and dialysis segments, responding to increased demand due to public health initiatives[38]. - The company’s innovative product features, such as the closed design of intravenous catheters, improve clinical safety and reduce the workload for healthcare professionals[41]. - The company is committed to meeting diverse clinical needs with a wide range of product specifications and designs in its injection product line[39]. - The company invested 23.1 million RMB in R&D, accounting for 4.54% of its revenue, and holds 73 authorized patents, indicating a strong commitment to innovation[68]. - The company is currently applying for 8 new medical device registrations, reflecting its ongoing efforts to expand its product portfolio[68]. Quality Control and Compliance - The company faces quality control risks as its main products are classified as Class III medical devices, which require strict adherence to safety and effectiveness standards[6]. - The company emphasizes the importance of maintaining effective quality management systems to avoid reputational damage and operational impacts[7]. - The company has a well-established quality management system, having obtained certifications from the EU CE and CMD, as well as FDA510(k) approval for some products[74]. - The company is focused on maintaining quality control to mitigate risks associated with its medical device products[102]. Financial Position and Assets - The total assets at the end of the reporting period were ¥1,233,157,081.49, a decrease of 0.93% from the end of the previous year[24]. - The net assets attributable to shareholders increased to ¥805,495,295.31, representing a growth of 2.58% compared to the end of the previous year[24]. - The company's cash and cash equivalents increased by 151.29% to ¥22,518,145.89, compared to a negative balance of ¥43,901,856.85 in the previous year[79]. - The company's total assets as of June 30, 2021, were CNY 1,099,983,355.17, a slight decrease from CNY 1,110,491,235.69 at the end of 2020[171]. - Total liabilities decreased to CNY 319,478,717.23 from CNY 337,867,985.97, indicating a reduction of 5.5%[172]. Corporate Governance and Shareholder Information - The company’s financial report has been confirmed as true, accurate, and complete by its board of directors and management[3]. - The total number of shareholders at the end of the reporting period is 22,632[149]. - 彭义兴 holds 24.79% of the shares, totaling 97,673,880 shares, with an increase of 32,557,960 shares during the reporting period[150]. - The company has a commitment that 75% of the shares held by directors and senior management will be locked during their tenure[146]. Social Responsibility and Community Engagement - The company actively participates in social responsibility initiatives, including creating job opportunities and supporting pandemic relief efforts[117].